Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vevesca: OGS said an Israeli ethics committee recommended lifting a suspension on Israeli trials of Vevesca (OGT 918) to treat Gaucher disease after reviewing a

Oxford GlycoSciences plc (LSE:OGS; OGSI), Oxford, U.K.
Product: Vevesca ( OGT 918)
Business:

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE